Phase 4 N=88 Gabapentin for Alcohol Withdrawal Syndrome
Alcohol Withdrawal Syndrome
Primary: Mean Length of Hospital Stay — 44.91; 50.50 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Remote Treatment of Alcohol Withdrawal
Alcohol Withdrawal
Primary: Retention in Treatment — 28 Participants — p=0.0021
N/A N=46 Treating Alcohol Withdrawal With Oral Baclofen
Alcohol Withdrawal Delirium
Primary: Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups — 14.1; 124.4 mg of benzodiazepine per 8 hours
N/A N=24 Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
Acute Alcohol Withdrawal
Primary: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal — 180.5; 112.5; 109.1 mg — p=0.64
N/A N=102 Phenobarbital for Acute Alcohol Withdrawal
Alcohol Withdrawal
Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants
Phase 2 N=49 Acamprosate to Reduce Symptoms of Alcohol Withdrawal
Alcohol-Related Disorders · Alcohol Dependence · Alcoholism
Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine
Phase 4 N=26 Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
Alcohol Withdrawal
Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale
Phase 2 N=52 Ibudilast and Withdrawal-Related Dysphoria
Alcohol Use Disorder
Primary: Negative Affect — 2.91; 2.47 units — p=.62
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Phase 2 N=50 Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065
Phase 3 N=60 Prometa Protocol for Alcohol Dependence
Alcohol Dependence
Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Phase 2 N=60 Human Laboratory Study of ASP8062 for Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Drinking · Alcohol Use Disorder (AUD)
Primary: Alcohol Craving — 6.44; 6.26 score on a scale — p=0.784
N/A N=53 Ketogenic Diet (KD) in Alcoholism
Alcoholism
Primary: Withdrawal Symptoms Measured Using the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) — 4.16; 6.57 score on a scale — p=0.067
Phase 2 N=26 Medication Development in Alcoholism: Suvorexant Versus Placebo
Alcohol Use Disorder (AUD)
Primary: Visual Analogue Scale (VAS) of Craving Severity: 2 Arms — 2.38; 1.44 score on a scale
N/A N=33 Alcohol Biosensor Monitoring for Alcoholic Liver Disease
Alcohol Use, Unspecified
Primary: Alcohol Use — 7.4; 5.3; 4.4 drinks per episode
Phase 1 N=14 Oxytocin Treatment of Alcohol Withdrawal
Alcohol Withdrawal
Primary: Total Lorazepam Dosage (in Milligrams) — 16.5; 3.4 milligrams of lorazepam
N/A N=94 Pharmacogenetics of Alcohol: Treatment Implications
Alcohol Related Disorders · Alcoholism · Alcohol Abuse
Primary: Breath Alcohol — 0.001; 0.075; 0.001; 0.071 gr/dL — p=0.28
Phase 2 N=20 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
Cannabis Dependence · Alcohol Dependence · Cannabis Use Disorder
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — 198.3; 55.9 ng/mg
Phase 4 N=163 A Randomized Clinical Trial of Alcohol Care Management
Alcohol Dependence
Primary: Treatment Engagement — 36; 9 percentage of participants engaged
Phase 4 N=90 Acamprosate in Alcoholics With Comorbid Anxiety or Depression
Alcohol Dependence · Major Depression · Social Anxiety Disorder
Primary: Percent Days Drinking — 34.9; 31.9 percentage of days drinking — p=0.64
Phase 2 N=150 Gabapentin Treatment of Alcohol Dependence
Alcoholism · Alcohol Dependence
Primary: Drinking — 6; 8; 2 participants — p=<0.04
Phase 1 N=91 The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders
Alcohol Use Disorder
Primary: Percent Drinking Days — 38.5; 46.6; 53 percentage of drinking days — p=0.009
Phase 2 N=50 Medication Development in Alcoholism: Investigating PPAR Agonists
Alcoholism
Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period — 8.94; 10.37; 9.83; 11.03 units on a…
Phase 2 N=150 ABT-436 for Alcohol Dependence
Alcohol Dependence · Alcohol Abuse · Alcohol Use Disorders
Primary: Weekly Percentage of Heaving Drinking Days — 37.6; 31.3 weekly percentage of heavy drinking days
Phase 2 N=51 Medication Development in Alcoholism: Apremilast Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 33.84; 28.31 score on a scale — p=0.36
Phase 3 N=75 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Bipolar Disorder · Alcoholism · Alcohol Abuse
Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day
Phase 2 N=114 Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation
Insomnia
Primary: Change From Baseline of Wakefulness After Sleep Onset (WASO) Measured by Polysomnography (PSG) — 100.88; 99.70; 103.51; 48.64 Minutes
N/A N=29 Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Substance Withdrawal Syndrome
Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…
N/A N=75 Clinical Intervention in Alcohol Use Disorder
Alcohol Use Disorder · Eligible to go Into the MRI Scanner · Short-term Abstinence From Alcohol Use (2 Week Abstinent)
Primary: Intervention Effects on Brain Functional Connectivity — 0.05; 0.19 percentage of Blood Oxygenation Level De